SE466259B
(sv)
*
|
1990-05-31 |
1992-01-20 |
Arne Forsgren |
Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
|
SE9201331D0
(sv)
*
|
1992-04-28 |
1992-04-28 |
Hightech Receptor C O Active |
Protein l och hybridproteiner daerav
|
US6153406A
(en)
*
|
1993-07-23 |
2000-11-28 |
North American Vaccine, Inc. |
Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
|
US6001564A
(en)
*
|
1994-09-12 |
1999-12-14 |
Infectio Diagnostic, Inc. |
Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
|
US20020055101A1
(en)
|
1995-09-11 |
2002-05-09 |
Michel G. Bergeron |
Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
|
NZ306316A
(en)
*
|
1995-04-17 |
2001-06-29 |
Smithkline Beecham Biolog S |
use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen
|
US5994066A
(en)
*
|
1995-09-11 |
1999-11-30 |
Infectio Diagnostic, Inc. |
Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
|
US20100267012A1
(en)
|
1997-11-04 |
2010-10-21 |
Bergeron Michel G |
Highly conserved genes and their use to generate probes and primers for detection of microorganisms
|
US20030049636A1
(en)
|
1999-05-03 |
2003-03-13 |
Bergeron Michel G. |
Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
|
US20050033022A1
(en)
*
|
1997-09-26 |
2005-02-10 |
Smithkline Beecham Biologicals Sa |
Fusion proteins comprising HIV-1 Tat and/or Nef proteins
|
GB9727262D0
(en)
*
|
1997-12-24 |
1998-02-25 |
Smithkline Beecham Biolog |
Vaccine
|
CZ298347B6
(cs)
|
1998-02-05 |
2007-09-05 |
Glaxosmithkline Biologicals S.A. |
Fúzní protein z rodiny MAGE, kódová sekvence nukleové kyseliny, vektor, hostitelská bunka, vakcina a použití fúzního proteinu pro výrobu vakciny
|
US6518256B1
(en)
|
1998-03-18 |
2003-02-11 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6312695B1
(en)
|
1998-03-18 |
2001-11-06 |
Corixa Corporation |
Compounds and methods for therapy of lung cancer
|
US6531315B1
(en)
|
1998-03-18 |
2003-03-11 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6426072B1
(en)
|
2000-08-02 |
2002-07-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6706262B1
(en)
|
1998-03-18 |
2004-03-16 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6660838B1
(en)
|
1998-03-18 |
2003-12-09 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6482597B1
(en)
|
1999-12-17 |
2002-11-19 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6696247B2
(en)
|
1998-03-18 |
2004-02-24 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US7579160B2
(en)
|
1998-03-18 |
2009-08-25 |
Corixa Corporation |
Methods for the detection of cervical cancer
|
US7049063B2
(en)
|
1998-03-18 |
2006-05-23 |
Corixa Corporation |
Methods for diagnosis of lung cancer
|
US6821518B1
(en)
|
1998-03-18 |
2004-11-23 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US7258860B2
(en)
|
1998-03-18 |
2007-08-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6737514B1
(en)
|
1998-12-22 |
2004-05-18 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6960570B2
(en)
|
1998-03-18 |
2005-11-01 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6342231B1
(en)
|
1998-07-01 |
2002-01-29 |
Akzo Nobel N.V. |
Haemophilus parasuis vaccine and diagnostic
|
EP2272859B1
(en)
|
1998-08-07 |
2014-10-22 |
University of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
WO2000034483A2
(en)
|
1998-12-08 |
2000-06-15 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
US7198920B1
(en)
*
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
JP2002537354A
(ja)
*
|
1999-02-25 |
2002-11-05 |
スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム |
ペプチド、及びH.influenzaeのプロテインD由来の担体を含む免疫原
|
WO2000056360A2
(en)
|
1999-03-19 |
2000-09-28 |
Smithkline Beecham Biologicals S.A. |
Vaccine against antigens from bacteriae
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
KR20020007354A
(ko)
|
1999-04-02 |
2002-01-26 |
길리스 스티브 |
폐암의 치료 및 진단에 유용한 화합물 및 방법
|
US20040040205A1
(en)
*
|
2002-04-25 |
2004-03-04 |
Weder Donald E. |
Wrapper with decorative extension and method
|
EP2322666A3
(en)
|
1999-09-28 |
2011-08-10 |
Geneohm Sciences Canada, Inc. |
Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms.
|
ES2389445T3
(es)
|
2000-02-23 |
2012-10-26 |
Glaxosmithkline Biologicals Sa |
Compuestos novedosos
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
ATE389020T1
(de)
|
2000-04-21 |
2008-03-15 |
Corixa Corp |
Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
|
SI1542732T1
(sl)
|
2000-06-20 |
2010-01-29 |
Corixa Corp Csc The United Sta |
Fuzijski proteini Mycobacterium tuberculosis
|
AU2001273149A1
(en)
|
2000-06-28 |
2002-01-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
EP1946769B1
(en)
|
2000-06-29 |
2012-05-30 |
SmithKline Beecham Biologicals S.A. |
Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
EP1317253A4
(en)
*
|
2000-07-28 |
2006-04-26 |
Univ Emory |
BIOLOGICAL COMPONENT COMPRISING AN ARTIFICIAL MEMBRANE
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
GB0025171D0
(en)
*
|
2000-10-13 |
2000-11-29 |
Smithkline Beecham Biolog |
Novel compounds
|
ES2377077T3
(es)
|
2000-10-18 |
2012-03-22 |
Glaxosmithkline Biologicals S.A. |
Vacunas que comprenden al antígeno MAGE unido a un fragmento de proteína D
|
GB0025998D0
(en)
*
|
2000-10-24 |
2000-12-13 |
Smithkline Beecham Biolog |
Novel compounds
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
WO2002088361A2
(en)
*
|
2001-04-30 |
2002-11-07 |
Glaxosmithkline Biologicals S.A. |
Haemophilus influenzae antigens
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
JP2003047482A
(ja)
*
|
2001-05-22 |
2003-02-18 |
Pfizer Prod Inc |
非アナフィラキシー誘発性IgEワクチン
|
EP2314712B1
(en)
*
|
2001-11-07 |
2014-01-08 |
Mannkind Corporation |
Expression vectors encoding epitopes of antigens and methods for their design
|
EP2224012B1
(en)
|
2001-12-17 |
2013-01-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
CA2492598C
(en)
|
2002-07-18 |
2013-12-17 |
University Of Washington |
Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
|
DE60335477D1
(de)
|
2002-10-11 |
2011-02-03 |
Novartis Vaccines & Diagnostic |
Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
EP2172213B1
(en)
|
2003-01-30 |
2013-04-03 |
Novartis AG |
Injectable vaccines against multiple meningococcal serogroups
|
GB0313916D0
(en)
|
2003-06-16 |
2003-07-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
PL1961426T3
(pl)
|
2003-10-02 |
2012-03-30 |
Gsk Vaccines S R L |
Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
|
JP2005112827A
(ja)
*
|
2003-10-10 |
2005-04-28 |
National Institute Of Advanced Industrial & Technology |
抗体アフィニティ担体
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
WO2006019906A1
(en)
|
2004-07-14 |
2006-02-23 |
The Regents Of The University Of California |
Biomarker for early detection of ovarian cancer
|
KR101505496B1
(ko)
|
2004-09-22 |
2015-03-25 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
ES2385045T3
(es)
|
2005-02-18 |
2012-07-17 |
Novartis Vaccines And Diagnostics, Inc. |
Inmunógenos de Escherichia coli uropatogénica
|
SI2351772T1
(sl)
|
2005-02-18 |
2016-11-30 |
Glaxosmithkline Biologicals Sa |
Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
UA97943C2
(ru)
|
2005-03-31 |
2012-04-10 |
ГлаксоСмитКлайн Байолоджикалз с.а. |
Вакцина против инфекции chlamydia
|
IL308456A
(en)
|
2005-04-08 |
2024-01-01 |
Wyeth Llc |
A multivalent pneumomuroral protein-polysaccharide conjugate preparation
|
JP2008536515A
(ja)
|
2005-04-18 |
2008-09-11 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
ワクチンの調製のためのb型肝炎ウイルス表面抗原の発現
|
DK2457926T3
(da)
|
2005-04-29 |
2015-01-05 |
Glaxosmithkline Biolog Sa |
Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
|
KR20130122810A
(ko)
|
2005-06-27 |
2013-11-08 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신 제조 방법
|
EP1931380A2
(en)
|
2005-09-01 |
2008-06-18 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Multiple vaccination including serogroup c meningococcus
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP3020411A1
(en)
|
2005-12-22 |
2016-05-18 |
GlaxoSmithKline Biologicals s.a. |
Vaccine
|
WO2007082105A2
(en)
|
2006-01-16 |
2007-07-19 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chlamydia vaccine
|
EA015561B1
(ru)
|
2006-01-17 |
2011-08-30 |
Арне Форсгрен |
НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE)
|
US7868139B2
(en)
|
2006-01-24 |
2011-01-11 |
Uab Research Foundation |
Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
|
ES2670231T3
(es)
|
2006-03-22 |
2018-05-29 |
Glaxosmithkline Biologicals S.A. |
Regímenes para inmunización con conjugados meningocócicos
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
JP2009531387A
(ja)
|
2006-03-30 |
2009-09-03 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
EP2390361A1
(en)
|
2006-06-02 |
2011-11-30 |
GlaxoSmithKline Biologicals SA |
Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IL7R gene
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
PL2066344T3
(pl)
|
2006-09-07 |
2011-10-31 |
Glaxosmithkline Biologicals Sa |
Skojarzona szczepionka zawierająca inaktywowany wirus polio
|
SI2114993T1
(sl)
|
2007-01-15 |
2012-12-31 |
Glaxosmithkline Biologicals S.A. |
Cepivo
|
US8309096B2
(en)
|
2007-01-15 |
2012-11-13 |
Glaxosmithkline Biologicals S.A. |
Fusion protein
|
EP3199176B1
(en)
|
2007-04-04 |
2020-02-19 |
Infectious Disease Research Institute |
Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
|
BRPI0810778A2
(pt)
|
2007-05-02 |
2011-09-13 |
Glaxosmithkline Biolog Sa |
kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
|
EP2148697B1
(en)
|
2007-05-24 |
2012-10-03 |
GlaxoSmithKline Biologicals S.A. |
Lyophilised cpg containing wt-1 composition
|
WO2009000825A2
(en)
|
2007-06-26 |
2008-12-31 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
EP3061462B1
(en)
|
2007-07-02 |
2019-02-27 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
JP5406839B2
(ja)
|
2007-09-17 |
2014-02-05 |
オンコメチローム サイエンシズ ソシエテ アノニム |
Mage−a発現の改良された検出
|
EP2200642B1
(en)
|
2007-10-19 |
2012-04-18 |
Novartis AG |
Meningococcal vaccine formulations
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
AU2009215364B2
(en)
|
2008-02-21 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Meningococcal fHBP polypeptides
|
WO2010032141A2
(en)
*
|
2008-09-17 |
2010-03-25 |
Hunter Immunology Limited |
Non-typeable haemophilus influenzae vaccines and their uses
|
CN102159998B
(zh)
*
|
2008-09-19 |
2013-11-13 |
小费利克斯舍尔勒尔照相和特种纸两合公司 |
用于激光打印方法的记录材料
|
BRPI0920041A2
(pt)
|
2008-10-06 |
2017-06-27 |
Univ Chicago |
composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
|
JP5689064B2
(ja)
|
2008-10-27 |
2015-03-25 |
ノバルティス アーゲー |
精製方法
|
KR101644221B1
(ko)
|
2008-12-09 |
2016-07-29 |
화이자 백신스 엘엘씨 |
IgE CH3 펩티드 백신
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
EP2367568A2
(en)
|
2008-12-17 |
2011-09-28 |
Novartis AG |
Meningococcal vaccines including hemoglobin receptor
|
US7876118B2
(en)
|
2009-02-05 |
2011-01-25 |
Advantest Corporation |
Test equipment
|
MX2011009597A
(es)
|
2009-03-17 |
2012-05-29 |
Glaxosmithkline Biolog Sa |
Deteccion mejorada de la expresion del gen.
|
CA2756522C
(en)
|
2009-03-24 |
2018-06-26 |
Novartis Ag |
Adjuvanting meningococcal factor h binding protein
|
WO2010109324A1
(en)
|
2009-03-24 |
2010-09-30 |
Novartis Ag |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
EP3281947B1
(en)
|
2009-04-03 |
2020-02-12 |
The University of Chicago |
Compositions and methods related to protein a (spa) variants
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
葛兰素史密丝克莱恩生物有限公司 |
用于免疫接种以抵御金黄色葡萄球菌的组合物
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
AU2010288240B2
(en)
|
2009-08-27 |
2014-03-27 |
Novartis Ag |
Hybrid polypeptides including meningococcal fHBP sequences
|
MY163512A
(en)
|
2009-09-03 |
2017-09-15 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
EP2475385A1
(en)
|
2009-09-10 |
2012-07-18 |
Novartis AG |
Combination vaccines against respiratory tract diseases
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
BR112012009014B8
(pt)
|
2009-09-30 |
2022-10-04 |
Novartis Ag |
Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
JP5960055B2
(ja)
|
2009-10-27 |
2016-08-02 |
ノバルティス アーゲー |
改変髄膜炎菌fHBPポリペプチド
|
RS56000B1
(sr)
|
2009-10-30 |
2017-09-29 |
Glaxosmithkline Biologicals Sa |
Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
MX2012008790A
(es)
|
2010-01-27 |
2012-08-17 |
Glaxosmithkline Biolog Sa |
Antigenos de tuberculosis modificados.
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
US8808699B2
(en)
|
2010-04-05 |
2014-08-19 |
The University Of Chicago |
Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
|
WO2011154878A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
AU2011268507B2
(en)
|
2010-06-25 |
2014-08-14 |
Novartis Ag |
Combinations of meningococcal factor H binding proteins
|
SG186290A1
(en)
|
2010-07-02 |
2013-01-30 |
Univ Chicago |
Compositions and methods related to protein a (spa) variants
|
EP2614074A1
(en)
|
2010-09-09 |
2013-07-17 |
The University of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
WO2012064659A1
(en)
|
2010-11-08 |
2012-05-18 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
EP2668299B1
(en)
*
|
2011-01-26 |
2018-03-07 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Selective detection of haemophilus influenzae
|
US10286056B2
(en)
|
2011-01-27 |
2019-05-14 |
Glaxosmithkline Biologicals S.A. |
Adjuvant nanoemulsions with crystallisation inhibitors
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
JP6191082B2
(ja)
|
2011-03-02 |
2017-09-06 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
より低用量の抗原および/またはアジュバントを有する混合ワクチン
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
EP2688590B1
(en)
|
2011-03-24 |
2020-02-12 |
GlaxoSmithKline Biologicals SA |
Adjuvant nanoemulsions with phospholipids
|
GB201105981D0
(en)
|
2011-04-08 |
2011-05-18 |
Glaxosmithkline Biolog Sa |
Novel process
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
WO2012170356A1
(en)
|
2011-06-04 |
2012-12-13 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6 of haemophilus influenzae
|
JP6088507B2
(ja)
|
2011-07-08 |
2017-03-01 |
ノバルティス アーゲー |
チロシンライゲーションの方法
|
WO2013014105A1
(en)
|
2011-07-22 |
2013-01-31 |
Glaxosmithkline Biologicals S.A. |
Prame purification
|
JP6078067B2
(ja)
|
2011-08-29 |
2017-02-08 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
炎症誘発性状態の治療および予防のためのhdl関連分子の使用
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2013068949A1
(en)
|
2011-11-07 |
2013-05-16 |
Novartis Ag |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
EP2592137A1
(en)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
EP2797624A1
(en)
|
2011-12-29 |
2014-11-05 |
Novartis AG |
Adjuvanted combinations of meningococcal factor h binding proteins
|
US20150132339A1
(en)
|
2012-03-07 |
2015-05-14 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
US20150125486A1
(en)
|
2012-03-08 |
2015-05-07 |
Novartis Ag |
Adjuvanted formulations of pediatric antigens
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
US9968668B2
(en)
|
2012-04-26 |
2018-05-15 |
The University Of Chicago |
Staphylococcal coagulase antigens and methods of their use
|
US10124051B2
(en)
|
2012-05-22 |
2018-11-13 |
Glaxosmithkline Biologicals Sa |
Meningococcus serogroup X conjugate
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
HUE065746T2
(hu)
|
2012-08-03 |
2024-06-28 |
Access To Advanced Health Inst |
Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
AU2013311702A1
(en)
|
2012-09-06 |
2015-02-19 |
Novartis Ag |
Combination vaccines with serogroup B meningococcus and D/T/P
|
ES2848048T3
(es)
|
2012-10-03 |
2021-08-05 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas
|
SG11201502599TA
(en)
|
2012-10-12 |
2015-05-28 |
Glaxosmithkline Biolog Sa |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
PL2925355T3
(pl)
|
2012-11-30 |
2018-06-29 |
Glaxosmithkline Biologicals S.A. |
Antygeny pseudomonas i połączenia antygenów
|
CN105188747A
(zh)
|
2013-02-01 |
2015-12-23 |
葛兰素史密斯克莱生物公司 |
包含toll样受体激动剂的免疫组合物的皮内递送
|
US9909114B2
(en)
|
2013-03-28 |
2018-03-06 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
WO2015033251A2
(en)
|
2013-09-08 |
2015-03-12 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
IL296681B2
(en)
|
2014-01-21 |
2024-09-01 |
Pfizer |
Immunogenic preparations including conjugated capsular saccharide antigens and their uses
|
EP3957321A3
(en)
|
2014-01-21 |
2022-07-13 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
HUE055553T2
(hu)
|
2014-01-21 |
2021-12-28 |
Pfizer |
Streptococcus pneumoniae kapszulás poliszacharidok és azok konjugátumai
|
CA2939416A1
(en)
|
2014-02-14 |
2015-08-20 |
Pfizer Inc. |
Immunogenic glycoprotein conjugates
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
CA2940447C
(en)
|
2014-02-28 |
2023-07-11 |
Glaxosmithkline Biologicals Sa |
Modified meningococcal fhbp polypeptides
|
EP3229833A1
(en)
|
2014-12-10 |
2017-10-18 |
GlaxoSmithKline Biologicals SA |
Method of treatment
|
EP3034516A1
(en)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification of streptococcal capsular polysaccharide
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
US20180071380A1
(en)
|
2015-03-20 |
2018-03-15 |
The Regents Of The University Of Michigan |
Immunogenic compositions for use in vaccination against bordetella
|
PE20240927A1
(es)
|
2015-07-21 |
2024-04-30 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US10993971B2
(en)
|
2015-12-04 |
2021-05-04 |
Dana-Farber Cancer Institute, Inc. |
Vaccination with MICA/B alpha 3 domain for the treatment of cancer
|
US11612664B2
(en)
|
2016-04-05 |
2023-03-28 |
Gsk Vaccines S.R.L. |
Immunogenic compositions
|
MX2018014270A
(es)
|
2016-05-21 |
2019-02-14 |
Infectious Disease Res Inst |
Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
|
WO2017220753A1
(en)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3269385A1
(en)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
US20180064801A1
(en)
|
2016-09-02 |
2018-03-08 |
Glaxosmithkline Biologicals Sa |
Vaccines for neisseria gonorrhoeae
|
BE1025162B9
(fr)
|
2016-12-06 |
2019-01-07 |
Glaxosmithkline Biologicals Sa |
Procede de purification pour les polysaccharides capsulaires
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
PL3570879T3
(pl)
|
2017-01-20 |
2022-06-20 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom
|
KR102650073B1
(ko)
|
2017-01-31 |
2024-03-20 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
|
AU2018215585B2
(en)
|
2017-01-31 |
2022-03-17 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
WO2018178264A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
BR112019025193A2
(pt)
|
2017-05-30 |
2020-06-23 |
Glaxosmithkline Biologicals S.A. |
Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
|
EP3641808A1
(en)
*
|
2017-08-14 |
2020-04-29 |
GlaxoSmithKline Biologicals S.A. |
Methods of boosting immune responses
|
FI3678654T3
(fi)
|
2017-09-07 |
2024-09-02 |
Merck Sharp & Dohme Llc |
Pneumokokkipolysakkaridit ja niiden käyttö immunogeenisissä polysakkaridi-kantajaproteiini-konjugaateissa
|
JP2021504424A
(ja)
|
2017-12-01 |
2021-02-15 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
サポニン精製
|
CN117982633A
(zh)
|
2017-12-06 |
2024-05-07 |
默沙东有限责任公司 |
包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
|
BR112021000529A2
(pt)
|
2018-07-19 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Processos para preparar polissacarídeos secos
|
BR112021000965A2
(pt)
|
2018-08-07 |
2021-04-27 |
Glaxosmithkline Biologicals S.A. |
processos e vacinas
|
EP3607967A1
(en)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Modified meningococcal fhbp polypeptides
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20220339282A1
(en)
|
2018-11-29 |
2022-10-27 |
Glaxosmithkline Biologicals Sa |
Methods for manufacturing an adjuvant
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
US20220054632A1
(en)
|
2018-12-12 |
2022-02-24 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
SG11202106541WA
(en)
|
2018-12-19 |
2021-07-29 |
Merck Sharp & Dohme |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
US20220118072A1
(en)
|
2019-02-11 |
2022-04-21 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP3956666A1
(en)
|
2019-04-18 |
2022-02-23 |
GlaxoSmithKline Biologicals S.A. |
Antigen binding proteins and assays
|
CN113966234A
(zh)
|
2019-05-10 |
2022-01-21 |
葛兰素史克生物有限公司 |
缀合物的产生
|
EP3980044A1
(en)
|
2019-06-05 |
2022-04-13 |
GlaxoSmithKline Biologicals SA |
Saponin purification
|
EP4003410A1
(en)
|
2019-07-31 |
2022-06-01 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
EP4009951A1
(en)
|
2019-08-05 |
2022-06-15 |
GlaxoSmithKline Biologicals S.A. |
Process for preparing a composition comprising a protein d polypeptide
|
CN114667158A
(zh)
|
2019-08-05 |
2022-06-24 |
葛兰素史克生物有限公司 |
免疫原性组合物
|
CN115605222A
(zh)
|
2019-09-27 |
2023-01-13 |
辉瑞公司(Us) |
脑膜炎奈瑟氏菌组合物及其方法
|
WO2021084429A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CN114728051A
(zh)
|
2019-11-22 |
2022-07-08 |
葛兰素史克生物有限公司 |
细菌糖糖缀合物疫苗的剂量和施用
|
BR112022015796A2
(pt)
|
2020-02-21 |
2022-10-11 |
Pfizer |
Purificação de sacarídeos
|
WO2021165928A2
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2021250626A2
(en)
|
2020-06-12 |
2021-12-16 |
Glaxosmithkline Biologicals Sa |
Dock tag system
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
EP4232593A1
(en)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
AU2021368151B2
(en)
|
2020-10-27 |
2024-09-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
EP4294433A1
(en)
|
2021-02-22 |
2023-12-27 |
GlaxoSmithKline Biologicals SA |
Immunogenic composition, use and methods
|
EP4333879A1
(en)
|
2021-05-03 |
2024-03-13 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP4346892A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CA3231684A1
(en)
|
2021-09-09 |
2023-03-16 |
Affinivax, Inc. |
Multivalent pneumococcal vaccines
|
IL314243A
(en)
|
2022-01-13 |
2024-09-01 |
Pfizer |
Immunogenic preparations containing conjugates of capsular sugar antigen and their uses
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2024017827A1
(en)
|
2022-07-19 |
2024-01-25 |
Glaxosmithkline Biologicals Sa |
Continuous process for vaccine production
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|